Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10


Mechanisms of Resistance to EGFR Inhibition Reveal Metabolic Vulnerabilities in Human GBM.

McKinney A, Lindberg OR, Engler JR, Chen KY, Kumar A, Gong H, Lu KV, Simonds EF, Cloughesy TF, Liau LM, Prados M, Bollen AW, Berger MS, Shieh JTC, James CD, Nicolaides TP, Yong WH, Lai A, Hegi ME, Weiss WA, Phillips JJ.

Mol Cancer Ther. 2019 Sep;18(9):1565-1576. doi: 10.1158/1535-7163.MCT-18-1330. Epub 2019 Jul 3.


Heparan Sulfate Glycosaminoglycans in Glioblastoma Promote Tumor Invasion.

Tran VM, Wade A, McKinney A, Chen K, Lindberg OR, Engler JR, Persson AI, Phillips JJ.

Mol Cancer Res. 2017 Nov;15(11):1623-1633. doi: 10.1158/1541-7786.MCR-17-0352. Epub 2017 Aug 4.


GBM heterogeneity as a function of variable epidermal growth factor receptor variant III activity.

Lindberg OR, McKinney A, Engler JR, Koshkakaryan G, Gong H, Robinson AE, Ewald AJ, Huillard E, David James C, Molinaro AM, Shieh JT, Phillips JJ.

Oncotarget. 2016 Nov 29;7(48):79101-79116. doi: 10.18632/oncotarget.12600.


Measuring sulfatase expression and invasion in glioblastoma.

Wade A, Engler JR, Tran VM, Phillips JJ.

Methods Mol Biol. 2015;1229:507-16. doi: 10.1007/978-1-4939-1714-3_39.


Proteoglycans and their roles in brain cancer.

Wade A, Robinson AE, Engler JR, Petritsch C, James CD, Phillips JJ.

FEBS J. 2013 May;280(10):2399-417. doi: 10.1111/febs.12109. Epub 2013 Feb 6. Review.


Increased microglia/macrophage gene expression in a subset of adult and pediatric astrocytomas.

Engler JR, Robinson AE, Smirnov I, Hodgson JG, Berger MS, Gupta N, James CD, Molinaro A, Phillips JJ.

PLoS One. 2012;7(8):e43339. doi: 10.1371/journal.pone.0043339. Epub 2012 Aug 22.


OCT-1 as a determinant of response to antileukemic treatment.

Engler JR, Hughes TP, White DL.

Clin Pharmacol Ther. 2011 Apr;89(4):608-11. doi: 10.1038/clpt.2011.12. Epub 2011 Feb 23. No abstract available.


OCT-1 function varies with cell lineage but is not influenced by BCR-ABL.

Engler JR, Zannettino AC, Bailey CG, Rasko JE, Hughes TP, White DL.

Haematologica. 2011 Feb;96(2):213-20. doi: 10.3324/haematol.2010.033290. Epub 2010 Oct 22.


The poor response to imatinib observed in CML patients with low OCT-1 activity is not attributable to lower uptake of imatinib into their CD34+ cells.

Engler JR, Frede A, Saunders V, Zannettino A, White DL, Hughes TP.

Blood. 2010 Oct 14;116(15):2776-8. doi: 10.1182/blood-2010-01-267013. Epub 2010 Jul 15.


Chronic myeloid leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 activity.

Engler JR, Frede A, Saunders VA, Zannettino AC, Hughes TP, White DL.

Leukemia. 2010 Apr;24(4):765-70. doi: 10.1038/leu.2010.16. Epub 2010 Feb 11.


Supplemental Content

Loading ...
Support Center